Elevance Health, Inc. (ELV): Filings, Insider Trades, Events

Quarter	Revenue	Net income	EPS
Q3 FY2026	$51.4B	$1.4B	6.27
Q2 FY2026	$50.5B	$1.5B	6.71
Q1 FY2026	$50.2B	$1.8B	8.00
Q4 FY2025	$49.7B	$547.0M	2.47

Form	Filed	Accepted (ET)
10-Q	21 Oct 2026	21 Oct, 2:14 PM
8-K	21 Oct 2026	21 Oct, 6:01 AM
8-K	10 Sep 2026
10-Q	15 Jul 2026
8-K	15 Jul 2026
11-K	17 Jun 2026
11-K	17 Jun 2026
8-K	10 Jun 2026

Financial statements

The income statement, balance sheet and cash flow by year and by quarter, line by line as the company reports them. Each column names the filing it comes from.

39 lines · 19 years · US$ millionsJSON

Fiscal period	FY2007	FY2008	FY2009	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Period ending	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Source filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Filed	18 Feb 2010	17 Feb 2011	22 Feb 2012	22 Feb 2013	20 Feb 2014	24 Feb 2015	19 Feb 2016	22 Feb 2017	21 Feb 2018	20 Feb 2019	19 Feb 2020	18 Feb 2021	16 Feb 2022	15 Feb 2023	21 Feb 2024	20 Feb 2025	6 Feb 2026	6 Feb 2026	6 Feb 2026
+Premiums	55,865M	57,101M	56,382M	53,974M	55,970M	56,497M	66,119M	68,390M	73,385M	78,860M^r	83,648M^r	85,421M	94,173M	104,109M	117,373M	133,229M	142,854M	144,166M	164,639M
+Product and service revenue	–	–	–	–	–	–	–	–	–	–	–	0M	2,760M	10,384M	12,657M	14,978M	19,452M	–	–
Service fees	617M	642M	606M	37M	41M	83M^r	40M	41M	43M	5,334M^r	5,413M^r	5,920M	6,208M^r	6,315M	6,913M	7,453M	7,903M	–	–
Total operating revenue	60,156M	61,579M	60,740M^r	57,741M^r	59,865M	60,514M^r	70,191M	73,022M	78,405M	84,194M	89,061M	91,341M	103,141M	120,808M	136,943M	155,660M	170,209M	175,204M	197,584M
+Net investment income	1,001M	851M	801M	803M	704M	686M	659M	724M	678M	779M^r	867M^r	970M	1,005M	877M	1,378M	1,485M	1,825M	2,051M	2,194M
Net realized gains on financial instruments	–	–	–	–	–	–	–	177M	158M	5M	145M	-206M	67M	182M	–	–	–	–	–
Total other-than-temporary impairment losses on investments	260M	1,208M	538M	71M	115M	41M	101M	56M	100M	147M^r	35M^r	29M	53M	–	–	–	–	–	–
Portion of other-than-temporary impairment losses recognized in other comprehensive income	0M	0M	-88M	-31M	-21M	-3.4M	-1.7M	-7.2M	-17M	-32M^r	-2M^r	-3M	-6M	–	–	–	–	–	–
Other-than-temporary impairment losses recognized in income	260M	1,208M	450M	39M	93M	38M	99M	49M	83M	115M^r	33M^r	26M	47M	–	–	–	–	–	–
+Net losses on financial instruments	–	–	–	–	–	–	–	–	–	–	–	–	67M	182M	318M	-550M	-694M	-445M	-653M
+Gain on sale of business	0M	0M	3,792M	–	–	–	–	–	–	–	–	–	–	–	–	0M	0M	201M	0M
Total revenues	61,168M	61,251M	64,940M^r	58,699M^r	60,711M	61,497M^r	71,024M	73,874M	79,157M	84,863M	90,040M^r	92,105M	104,213M	121,867M	138,639M	156,595M	171,340M	177,011M	199,125M
+Benefit expense	46,037M	48,266M^r	47,122M^r	44,930M^r	47,648M	48,214M	56,237M	56,855M	61,117M	66,834M^r	72,236M^r	71,895M	81,786M	88,045M	102,571M^r	116,642M^r	124,330M	127,567M	148,223M
+Cost of products sold	433M	469M	419M	0M	0M	137M	–	–	–	–	0M	0M	1,992M	8,953M	10,895M	13,035M	17,293M	19,750M	21,178M
+Operating expense	8,702M	8,497M^r	9,019M^r	8,733M^r	8,436M	8,681M^r	9,953M	11,748M	12,535M	12,559M^r	12,650M^r	14,020M	13,364M	17,450M	15,918M^r	17,700M^r	20,087M	20,025M	20,984M
+Interest expense	448M	470M	447M	419M	430M	512M	603M	601M	653M	723M	739M	753M	746M	784M	798M	851M	1,030M	1,185M	1,402M
+Amortization of other intangible assets	291M	286M	266M	242M	239M	233M^r	245M	221M	230M	192M^r	169M^r	358M	338M	361M	441M	767M	885M	580M	628M
Loss on extinguishment of debt	–	–	–	–	0M	0M	-145M	-81M	9.3M	0M	-282M^r	-11M	-2M	-36M	-21M	0M	0M	–	–
−Total expenses	55,910M	58,129M	57,537M^r	54,345M^r	56,753M	57,639M^r	67,183M	69,506M	74,526M	80,308M^r	86,076M^r	87,037M	98,228M	115,629M	130,644M^r	148,995M^r	163,625M	169,107M	192,415M
Income before income tax expense	5,258M	3,122M	7,403M	4,354M	3,958M	3,858M	3,840M	4,368M	4,631M	4,555M^r	3,964M^r	5,068M	5,985M	6,238M	7,995M^r	7,600M^r	7,715M	7,904M	6,710M
% of total operating revenue	8.7%	5.1%	12.2%	7.5%	6.6%	6.4%	5.5%	6.0%	5.9%	5.4%	4.5%	5.5%	5.8%	5.2%	5.8%	4.9%	4.5%	4.5%	3.4%
−Income tax expense	1,913M	632M	2,657M	1,467M	1,311M	1,207M^r	1,206M	1,808M	2,071M	2,085M^r	121M	1,318M	1,178M	1,666M	1,846M^r	1,712M^r	1,724M	1,933M	1,049M
Net income	–	–	–	–	–	–	–	–	–	–	–	–	4,807M	4,572M	6,149M^r	5,888M^r	5,991M	5,971M	5,661M
% of total operating revenue													4.7%	3.8%	4.5%	3.8%	3.5%	3.4%	2.9%
−Net loss attributable to noncontrolling interests	–	–	–	–	–	–	–	–	–	–	–	–	0M	0M	-9M	-6M	4M	-9M	-1M
Shareholders net income	3,345M	2,491M	4,746M	2,887M	2,647M	2,656M	2,490M	2,570M	2,560M	2,470M^r	3,843M^r	3,750M	4,807M	4,572M	6,158M^r	5,894M^r	5,987M	5,980M	5,662M
Basic	5.64	4.79	9.96	7.03	7.35	8.26	8.34	9.31	9.73	9.39	14.70	14.53	18.81	18.23	25.26	24.56^r	25.38	25.81	25.28
Diluted	5.56	4.76	9.88	6.94	7.25	8.18	8.20	8.99	9.38	9.21	14.35	14.19	18.47	17.98	24.95	24.28^r	25.22	25.68	25.21
Dividends per share	–	–	–	0.00	1.00	1.15	1.50	1.75	2.50	2.60	2.70	3.00	3.20	3.80	4.52	5.12	5.92	–	–

Hover a figure for its source.^r restated in a later filing– not reported in that period

Lines in the order and wording of the 10-K filed 6 Feb 2026. 314 of 318 subtotals add up to the company's own totals, and the balance sheet balances in 87 of 87 periods. Newest filing read: 15 Jul 2026.

Free for personal research, with credit (Data by Shikshan Nivesh) and a link. API access, bulk files and commercial use need a licence: the data licence.

Charts

Any figure or ratio in the record, by year, by quarter or on a trailing twelve months, as a value or as growth, against a peer if you like. Hover for the figures.

Revenue · quarterly · US$

Latest Jun 2026: $50.47B

ELV · Elevance Health, Inc.From2009to2026

Revenue = rev

$50.5B · Jun 2026

1.4% · Jun 2026

0.6% · Jun 2026

2.5% · Jun 2026

$1.5B · Jun 2026

$6.3B · Jun 2026

$6.71 · Jun 2026

224.6M · Dec 2025

$10.2B · Jun 2026

$4.3B · Dec 2025

Operating cash flowCapital spending

$5.92 · Dec 2023

Price at its own past P/E range

ELV $439.89 · 19.6× P/E · 23 Oct 2026

Month-end priceAt its median P/E, 18.2×Between its 10th and 90th percentile, 13.8× to 25.2×

Method. Each month-end, the trailing-twelve-month diluted EPS known that month (from filings filed by then) at the 10th, 50th and 90th percentile of this stock's own month-end P/E from 2014-12 to 2026-10. Months with the figure at or below zero are left out. A summary of the multiples the stock has traded at, not a value.

Ratios

Every ratio, worked out the same way for every company, by year or on a trailing twelve months. Hover a ratio for its formula.

145 ratios · 8 in profitabilityJSON

Fiscal year ending	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Return on common equity	–	–	20.5%	11.9%	11.2%	11.3%	10.3%	10.5%	10.8%	10.3%	14.9%	13.6%	16.0%	14.1%	17.8%	16.3%	15.8%	14.8%	13.3%
Return on assets	–	–	9.4%	5.6%	5.2%	4.8%	4.2%	4.2%	4.1%	3.9%	5.7%	5.3%	6.5%	5.6%	6.7%	5.9%	5.7%	5.3%	4.8%
Pretax margin	8.6%	5.1%	11.4%	7.4%	6.5%	6.3%	5.4%	5.9%	5.9%	5.4%	4.4%	5.5%	5.7%	5.1%	5.8%	4.9%	4.5%	4.5%	3.4%
Profit margin	5.5%	4.1%	7.3%	4.9%	4.4%	4.3%	3.5%	3.5%	3.2%	2.9%	4.3%	4.1%	4.6%	3.8%	4.4%	3.8%	3.5%	3.4%	2.8%
Net income to common margin	5.5%	4.1%	7.3%	4.9%	4.4%	4.3%	3.5%	3.5%	3.2%	2.9%	4.3%	4.1%	4.6%	3.8%	4.4%	3.8%	3.5%	3.4%	2.8%
Effective tax rate	36.4%	20.2%	35.9%	33.7%	33.1%	31.3%	31.4%	41.4%	44.7%	45.8%	3.1%	26.0%	19.7%	26.7%	23.1%	22.5%	22.3%	24.5%	15.6%
Dividend payout ratio	–	–	–	0.0%	13.5%	13.8%	18.0%	18.7%	25.6%	27.7%	18.3%	20.7%	17.0%	20.9%	17.9%	20.9%	23.3%	25.2%	27.0%
Sustainable growth rate	–	–	–	11.9%	9.7%	9.7%	8.4%	8.5%	8.0%	7.4%	12.2%	10.8%	13.2%	11.1%	14.6%	12.9%	12.1%	11.1%	9.7%

Hover a ratio for its formula as computed; avg() is the mean of the line now and a year earlier. The bar mark charts it. Worked out the same way for every company, from the standardized statements. Newest filing read: 15 Jul 2026.

What the company said with its results

The key points, guidance and management's own words from each of the last four results releases.

Key points

Operating revenue up 0.7 percent
Operating revenue reached $50.4 billion, up $0.4 billion, on higher premium yields, CarelonRx product revenue and service fees, partly offset by lower risk membership in several businesses.
Quarterly EPS rose with non-operating benefit
Diluted EPS was $6.27 against $5.32 a year earlier, and adjusted diluted EPS was $6.99 against $6.03. Management attributes results to operating performance and a $1.85 per-share net non-operating benefit.
Nine-month adjusted EPS nearly flat
Nine-month diluted EPS was $21.01 against $22.67. Nine-month adjusted diluted EPS was $27.06 against $26.88, up 0.7 percent.
Operating margin slightly lower
Total operating margin was 2.5 percent against 2.6 percent for the quarter and 3.4 percent against 4.6 percent for nine months. Adjusted operating margin for the quarter was 2.7 percent, unchanged.
Health Benefits gain fell
Health Benefits operating gain fell to $0.4 billion, with margin at 1.0 percent against 1.4 percent. Management ties the decline to targeted investments in its long-term operating model.
Health Benefits revenue rose on yields
Health Benefits revenue grew on higher premium yields and service fees, partly offset by lower Medicare Advantage, Medicaid and Employer Group risk membership.
Carelon revenue and gain both rose
Carelon operating revenue was $19.3 billion, up 5 percent, and its operating gain was $0.9 billion, up 17 percent, with margin at 4.7 percent against 4.2 percent.
Carelon Services gain up one-third
Carelon Services operating gain was $292 million against $219 million, and its margin was 3.8 percent against 3.0 percent.
Medical membership down 1.1 percent
Medical membership was 44.9 million, down 487 thousand from a year earlier. Management attributes the decline to lower enrollment in Medicaid, Medicare Advantage and Employer Group risk-based businesses.
Medicare Advantage membership fell 15.5 percent
Medicare Advantage membership was 1.898 million against 2.245 million a year earlier, and up 0.1 percent from June 30.
Commercial fee-based membership grew
Commercial fee-based membership reached 27.6 million, up 2.2 percent, and BlueCard membership rose 3.2 percent to 6.6 million.
Scripts and service consumers declined
CarelonRx quarterly adjusted scripts were 82.6 million, down 2.8 percent, and Carelon Services consumers served were 91.0 million, down 6.8 percent from a year earlier.
Benefit expense ratio improved
Benefit expense was 90.6 percent of premiums, 70 basis points better than a year earlier, which management attributes to Medicare Advantage and Individual ACA performance.
Days in claims payable lengthened
Days in claims payable were 44.9 at September 30, up 3.5 days year over year, against 45.4 days at June 30.

Guidance

Diluted EPSat least $22.00FY 2026 · raised from at least $20.10
Adjusted diluted EPSat least $29.00FY 2026 · raised from at least $27.00
Operating cash flowat least $6.5 billionFY 2026 · raised from at least $6.0 billion
Adjusted EPS growthat least 12%2027 · kept
Earnings baselineat least $26.752026 earnings baseline · new
Net adjustment items$7.00FY 2026 · raised from $6.90

In their words

“Elevance Health's third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business.” Gail K. Boudreaux President and Chief Executive Officer

“We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.75” Gail K. Boudreaux President and Chief Executive Officer

“By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value for our shareholders.” Gail K. Boudreaux President and Chief Executive Officer

Coming up

Fourth quarter dividend payable. A fourth quarter dividend of $1.72 per share is payable December 18, 2026, to holders of record on December 4, 2026.

Call replay available until November 20. The replay of the third quarter call is available until the end of the day on November 20, 2026.

Revenue by segment

As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.

This company reports no segment split in its annual report.

Company events

Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.


21 Oct 2026	21 Oct, 6:01 AM ET	8-K	Results	2.02, 9.01
10 Sep 2026		8-K	Investor update	7.01
15 Jul 2026		8-K	Results	2.02, 9.01
10 Jun 2026		8-K	Investor update	7.01
13 May 2026		8-K	Shareholder vote	5.07
22 Apr 2026		8-K	Results	2.02, 9.01
10 Mar 2026		8-K	Investor update	7.01
2 Mar 2026		8-K	Other events	8.01
26 Feb 2026		8-K	Leadership changeInvestor update	5.02, 7.01
28 Jan 2026		8-K	Results	2.02, 9.01
10 Dec 2025		8-K	Leadership change	5.02
10 Nov 2025		8-K	Investor update	7.01
21 Oct 2025		8-K	Results	2.02, 9.01
15 Sep 2025		8-K	Other events	8.01, 9.01
4 Sep 2025		8-K	Investor update	7.01
28 Jul 2025		8-K	Leadership change	5.02, 9.01
17 Jul 2025		8-K	Results	2.02, 9.01
28 May 2025		8-K	Investor update	7.01
14 May 2025		8-K	Shareholder vote	5.07
22 Apr 2025		8-K	Results	2.02, 9.01
17 Apr 2025		8-K	ResultsInvestor update	2.02, 7.01
10 Mar 2025		8-K	Investor update	7.01
23 Jan 2025		8-K	Results	2.02, 9.01
31 Oct 2024		8-K	Other events	8.01, 9.01
17 Oct 2024		8-K	Results	2.02, 9.01
17 Jul 2024		8-K	Results	2.02
12 Jun 2024		8-K	Investor update	7.01
30 May 2024		8-K	Other events	8.01, 9.01
15 May 2024		8-K	Shareholder vote	5.07
18 Apr 2024		8-K	Results	2.02, 9.01
4 Mar 2024		8-K	Investor update	7.01
25 Jan 2024		8-K	Other events	8.01
24 Jan 2024		8-K	Results	2.02, 9.01
18 Oct 2023		8-K	Results	2.02, 9.01
13 Oct 2023		8-K	Investor update	7.01
5 Oct 2023		8-K	Bylaws or fiscal year change	5.03, 9.01
20 Sep 2023		8-K	Investor update	7.01
8 Aug 2023		8-K	Leadership changeInvestor update	5.02, 7.01, 9.01
19 Jul 2023		8-K	Results	2.02, 9.01
13 Jun 2023		8-K	Investor update	7.01
11 May 2023		8-K	Shareholder vote	5.07
19 Apr 2023		8-K	Results	2.02, 9.01
22 Mar 2023		8-K	Investor update	7.01
22 Feb 2023		8-K	Leadership change	5.02
8 Feb 2023		8-K	Other events	8.01, 9.01
25 Jan 2023		8-K	Results	2.02, 9.01
4 Nov 2022		8-K	Other events	8.01, 9.01
25 Oct 2022		8-K	Leadership change	5.02, 9.01
19 Oct 2022		8-K	Results	2.02, 9.01
20 Jul 2022		8-K	Results	2.02, 9.01

1–50 of 150

8-K events each year

0102030

'04'08'12'16'20'24'26

Every filing

The company's filings with the SEC, newest first: 830 held. Insider, fund and large-holder filings have their own tables below.


21 Oct 2026	10-Q	30 Sep 2026	21 Oct, 2:14 PM ET
21 Oct 2026	8-K	21 Oct 2026	21 Oct, 6:01 AM ET
10 Sep 2026	8-K	10 Sep 2026
15 Jul 2026	10-Q	30 Jun 2026
15 Jul 2026	8-K	15 Jul 2026
17 Jun 2026	11-K	31 Dec 2025
17 Jun 2026	11-K	31 Dec 2025
10 Jun 2026	8-K	10 Jun 2026
13 May 2026	8-K	13 May 2026
22 Apr 2026	10-Q	31 Mar 2026
22 Apr 2026	8-K	22 Apr 2026
7 Apr 2026	PX14A6G	–
27 Mar 2026	DEFA14A	–
27 Mar 2026	DEF 14A	13 May 2026
10 Mar 2026	8-K	10 Mar 2026
2 Mar 2026	8-K	2 Mar 2026
26 Feb 2026	8-K	26 Feb 2026
6 Feb 2026	10-K	31 Dec 2025
28 Jan 2026	8-K	28 Jan 2026
10 Dec 2025	8-K	10 Dec 2025
10 Nov 2025	8-K	10 Nov 2025
21 Oct 2025	10-Q	30 Sep 2025
21 Oct 2025	8-K	21 Oct 2025
15 Sep 2025	8-K	8 Sep 2025
4 Sep 2025	8-K	4 Sep 2025
28 Jul 2025	8-K	28 Jul 2025
17 Jul 2025	10-Q	30 Jun 2025
17 Jul 2025	8-K	17 Jul 2025
24 Jun 2025	11-K	31 Dec 2024
24 Jun 2025	11-K	31 Dec 2024
28 May 2025	8-K	28 May 2025
14 May 2025	8-K	14 May 2025
22 Apr 2025	10-Q	31 Mar 2025
22 Apr 2025	8-K	22 Apr 2025
17 Apr 2025	8-K	17 Apr 2025
14 Apr 2025	PX14A6G	–
28 Mar 2025	DEFA14A	–
28 Mar 2025	DEFA14A	–
28 Mar 2025	DEF 14A	14 May 2025
10 Mar 2025	8-K	10 Mar 2025
20 Feb 2025	10-K	31 Dec 2024
23 Jan 2025	8-K	23 Jan 2025
31 Oct 2024	8-K	22 Oct 2024
17 Oct 2024	10-Q	30 Sep 2024
17 Oct 2024	8-K	17 Oct 2024
17 Jul 2024	10-Q	30 Jun 2024
17 Jul 2024	8-K	17 Jul 2024
20 Jun 2024	11-K	31 Dec 2023
12 Jun 2024	8-K	12 Jun 2024
30 May 2024	8-K	20 May 2024

1–50 of 150

Insider trades

Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.


22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	400	$434.00	$173.6K	30,103	23 Oct 2026
22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	321	$435.25	$139.7K	29,782	23 Oct 2026
22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	1,660	$436.20	$724.1K	28,122	23 Oct 2026
22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	560	$437.07	$244.8K	27,562	23 Oct 2026
22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	240	$438.22	$105.2K	27,322	23 Oct 2026
22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	1,160	$439.25	$509.5K	26,162	23 Oct 2026
22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	1,720	$440.44	$757.6K	24,442	23 Oct 2026
22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	2,343	$441.34	$1.0M	22,099	23 Oct 2026
22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	480	$442.61	$212.5K	21,619	23 Oct 2026
22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	440	$443.81	$195.3K	21,179	23 Oct 2026
22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	160	$444.85	$71.2K	21,019	23 Oct 2026
22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	827	$446.05	$368.9K	20,192	23 Oct 2026
22 Oct 2026	Kaye MarkEVP & CFO	Sale outside a trading plan	273	$447.19	$122.1K	19,919	23 Oct 2026
17 Jul 2026	Peru Ramiro GDirector	Purchase	1,000	$366.05	$366.1K	10,908	17 Jul 2026
17 Jul 2026	Boudreaux GailPresident and CEO	Purchase	680	$366.41	$249.2K	169,931	17 Jul 2026
17 Jul 2026	Boudreaux GailPresident and CEO	Purchase	2,045	$368.25	$753.1K	171,976	17 Jul 2026
12 Jun 2026	Penczek Ronald WCAO & Controller	Sale outside a trading plan	369	$403.16	$148.8K	3,740	15 Jun 2026
11 Jun 2026	Dixon Robert L JrDirector	Sale outside a trading plan	151	$401.77	$60.7K	10,734	12 Jun 2026
19 May 2026	Penczek Ronald WCAO & Controller	Sale outside a trading plan	1,531	$403.13	$617.2K	4,109	20 May 2026
12 Mar 2026	Schulman Amy WDirector	Sale outside a trading plan	26	$287.50	$7.5K	218	23 Mar 2026
6 Mar 2026	Kendrick Charles Morgan JrEVP & President, Commercial	Sale outside a trading plan	3,196	$284.92	$910.6K	11,791	9 Mar 2026
5 Mar 2026	Collis Steven HDirector	Purchase	3,000	$289.84	$869.5K	3,639	6 Mar 2026

Planned insider sales

Form 144 notices, filed when the sell order goes to the broker.


22 Oct 2026	MARK B KAYEOfficer	10,584	$4.7M	22 Oct 2026
7 Jul 2026	CLARK R KERRYDirector	1,500	$629.9K	7 Jul 2026
12 Jun 2026	RONALD WILLIAM PENCZEKOfficer	369	$148.8K	12 Jun 2026
11 Jun 2026	Dixon Robert L JRDirector	151	$60.7K	11 Jun 2026
19 May 2026	RONALD WILLIAM PENCZEKOfficer	1,531	$617.2K	19 May 2026
6 Mar 2026	CHARLES MORGAN KENDRICKOfficer	3,196	$910.6K	6 Mar 2026

Large holders

Schedule 13D and 13G filings by holders of more than 5% of the voting shares.


29 Apr 2026	Vanguard Capital Management	13G	7.13%	16.6M
26 Mar 2026	The Vanguard Group	13G amended	0%	0

Trades by members of the House

From each member's periodic transaction report: the amount is the band the report gives.


5 Aug 2025	Gilbert CisnerosCA31	Purchase	$1,001 - $15,000	Self	12 Sep 2025
29 Oct 2024	Valerie HoyleOR04	Purchase	$1,001 - $15,000	SP	12 Sep 2025
13 Jan 2025	Valerie HoyleOR04	Sale	$1,001 - $15,000	SP	12 Sep 2025
13 Aug 2025	Lisa McClainMI09	Sale	$1,001 - $15,000	SP	12 Sep 2025
24 Jun 2025	Lisa McClainMI09	Purchase	$1,001 - $15,000	SP	13 Aug 2025
10 Jul 2025	Lisa McClainMI09	Purchase	$1,001 - $15,000	SP	13 Aug 2025
12 May 2025	Jefferson ShreveIN06	Sale	$15,001 - $50,000	Self	22 Jun 2025
30 May 2025	Gilbert CisnerosCA31	Sale	$1,001 - $15,000	Self	6 Jun 2025
15 May 2025	Rob BresnahanPA08	Sale	$15,001 - $50,000	Self	31 May 2025
11 Apr 2025	Dan NewhouseWA04	Sale (partial)	$1,001 - $15,000	SP	16 May 2025
29 Apr 2025	Gilbert CisnerosCA31	Purchase	$1,001 - $15,000	Self	6 May 2025
10 Mar 2025	Jared MoskowitzFL23	Sale	$1,001 - $15,000	DC	8 Apr 2025
24 Feb 2025	Jefferson ShreveIN06	Purchase	$15,001 - $50,000	Self	9 Mar 2025
13 Jan 2025	Rob BresnahanPA08	Sale	$1,001 - $15,000	JT	13 Feb 2025
8 Nov 2024	Jared MoskowitzFL23	Purchase	$1,001 - $15,000	DC	9 Dec 2024
4 Sep 2024	John JamesMI10	Sale	$1,001 - $15,000	Self	6 Sep 2024
10 Nov 2023	John JamesMI10	Purchase	$1,001 - $15,000	Self	2 Sep 2024
16 Nov 2023	John JamesMI10	Purchase	$1,001 - $15,000	Self	2 Sep 2024
13 Feb 2024	Jared MoskowitzFL23	Purchase	$1,001 - $15,000	Self	21 Aug 2024
1 Feb 2024	Jared MoskowitzFL23	Purchase	$1,001 - $15,000	Self	21 Aug 2024
5 Jul 2024	Jared MoskowitzFL23	Purchase	$1,001 - $15,000	DC	6 Aug 2024
1 Jul 2024	Jared MoskowitzFL23	Purchase	$1,001 - $15,000	DC	6 Aug 2024
10 Apr 2024	Dan NewhouseWA04	Purchase	$1,001 - $15,000	SP	25 Apr 2024
4 Dec 2023	John CurtisUT03	Sale	$1,001 - $15,000	JT	15 Dec 2023
26 Sep 2023	Greg StantonAZ04	Purchase	$1,001 - $15,000	SP	9 Nov 2023
24 Oct 2023	Greg StantonAZ04	Sale	$1,001 - $15,000	SP	9 Nov 2023
5 Jul 2023	Rick LarsenWA02	Sale	$1,001 - $15,000	Self	17 Jul 2023
6 Jan 2023	Rick LarsenWA02	Purchase	$1,001 - $15,000	Self	26 May 2023
26 Apr 2023	John CurtisUT03	Purchase	$1,001 - $15,000	JT	10 May 2023
3 Jan 2023	Robert J. WittmanVA01	Sale (partial)	$1,001 - $15,000	Self	15 Feb 2023
20 Dec 2022	John CurtisUT03	Sale	$1,001 - $15,000	JT	10 Jan 2023

Short interest

Shares sold short and not yet bought back, on every FINRA settlement date.

Shares short, each settlement


30 Sep 2026	4.9M	-9.02%	3.92
15 Sep 2026	5.3M	-2.74%	4.21
31 Aug 2026	5.5M	+1.48%	6.56
14 Aug 2026	5.4M	-3.23%	5.67
31 Jul 2026	5.6M	-7.29%	3.93
15 Jul 2026	6.0M	+0.26%	3.52
30 Jun 2026	6.0M	-4.33%	3.27
15 Jun 2026	6.3M	-4.89%	3.52
29 May 2026	6.6M	+8.25%	4.34
15 May 2026	6.1M	+18.27%	3.68

1–10 of 103

Funds that hold it

Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.

Funds holding

1,721

quarter to 30 Jun 2026

Added or new

806

since 31 Mar 2026

Trimmed

537

in the quarter

Largest holder

BlackRock, Inc.

$7.3B

The 60 largest of 1,721 funds, by value


BlackRock, Inc.	$7.3B	19.0M	-896.0K	Trimmed	0.11%	Filing ↗
Vanguard Capital Management LLC	$5.4B	14.1M	-287.3K	Trimmed	0.12%	Filing ↗
State Street Corp.	$4.0B	10.4M	+137.9K	Added	0.12%	Filing ↗
Wellington Management Group LLP	$3.6B	9.2M	+985.0K	Added	0.61%	Filing ↗
First Eagle Investment Management, LLC	$3.2B	8.4M	–	Held	2.69%	Filing ↗
Vanguard Portfolio Management LLC	$2.4B	6.2M	-141.7K	Trimmed	0.11%	Filing ↗
Sanders Capital, LLC	$2.3B	5.8M	-69.3K	Trimmed	2.26%	Filing ↗
Geode Capital Management, LLC	$2.0B	5.2M	-26.6K	Trimmed	0.11%	Filing ↗
Harris Associates L P	$1.9B	4.9M	+128.0K	Added	2.53%	Filing ↗
Artisan Partners Limited Partnership	$1.8B	4.6M	-546.0K	Trimmed	2.89%	Filing ↗
Invesco Ltd.	$1.6B	4.2M	-583.2K	Trimmed	0.13%	Filing ↗
Price T Rowe Associates Inc.	$1.6B	4.0M	-731.6K	Trimmed	0.16%	Filing ↗
Norges Bank	$1.5B	4.0M	–	Held	0.15%	Filing ↗
Bank of New York Mellon Corp	$1.2B	3.2M	+377.5K	Added	0.20%	Filing ↗
FMR LLC	$1.2B	3.1M	+1.2M	Added	0.05%	Filing ↗
Morgan Stanley	$1.0B	2.6M	-23.3K	Trimmed	0.05%	Filing ↗
Northern Trust Corp.	$817.9M	2.1M	-43.0K	Trimmed	0.10%	Filing ↗
Citigroup Inc.	$810.9M	2.1M	+1.9M	Added	0.38%	Filing ↗
UBS AM, a distinct business unit of UBS Asset Management Americas LLC	$798.8M	2.1M	-453.1K	Trimmed	0.15%	Filing ↗
Hotchkis & Wiley Capital Management LLC	$779.7M	2.0M	-175.4K	Trimmed	2.27%	Filing ↗
Goldman Sachs Group Inc.	$775.6M	2.0M	+529.4K	Added	0.08%	Filing ↗
Nuveen, LLC	$769.5M	2.0M	+29.2K	Added	0.18%	Filing ↗
Massachusetts Financial Services Co.	$749.4M	1.9M	-300.2K	Trimmed	0.24%	Filing ↗
Bank of America Corp.	$698.5M	1.8M	-912.5K	Trimmed	0.04%	Filing ↗
Charles Schwab Investment Management Inc.	$697.5M	1.8M	+33.2K	Added	0.09%	Filing ↗
Legal & General Group Plc	$688.5M	1.8M	-102.1K	Trimmed	0.14%	Filing ↗
Grantham, Mayo, Van Otterloo & Co. LLC	$654.2M	1.7M	-246.6K	Trimmed	1.47%	Filing ↗
Amundi	$636.0M	1.6M	-1.0M	Trimmed	0.15%	Filing ↗
Dimensional Fund Advisors LP	$601.1M	1.6M	-91.4K	Trimmed	0.11%	Filing ↗
Manufacturers Life Insurance Company, the	$591.1M	1.5M	-549.9K	Trimmed	0.46%	Filing ↗
Eagle Capital Management LLC	$576.8M	1.5M	-57.2K	Trimmed	1.76%	Filing ↗
SG Americas Securities, LLC	$530.6M	1.4M	+575.5K	Added	0.31%	Filing ↗
Arrowstreet Capital, Limited Partnership	$511.7M	1.3M	+97.4K	Added	0.23%	Filing ↗
Baupost Group LLC	$493.1M	1.3M	0	Held	9.11%	Filing ↗
Vanguard Fiduciary Trust Co.	$461.5M	1.2M	-49.1K	Trimmed	0.10%	Filing ↗
Acadian Asset Management LLC	$445.6M	1.2M	+940.9K	Added	0.53%	Filing ↗
Baillie Gifford & Co.	$418.9M	1.1M	-89.6K	Trimmed	0.38%	Filing ↗
JPMorgan Chase & Co.	$386.9M	997.2K	-72.7K	Trimmed	0.02%	Filing ↗
Ruane, Cunniff & Goldfarb L.P.	$378.8M	979.6K	-408.4K	Trimmed	5.89%	Filing ↗
Brave Warrior Advisors, LLC	$377.8M	976.9K	-145.4K	Trimmed	8.23%	Filing ↗
Newport Trust Company, LLC	$369.3M	954.9K	-30.3K	Trimmed	0.89%	Filing ↗
Deutsche Bank AG	$364.7M	943.1K	+19.6K	Added	0.11%	Filing ↗
Franklin Resources Inc.	$360.8M	933.0K	+111.4K	Added	0.08%	Filing ↗
1832 Asset Management L.P.	$355.1M	918.2K	+144.1K	Added	0.44%	Filing ↗
Citadel Advisors LLC	$350.5M	906.4K	-655.8K	Trimmed	0.20%	Filing ↗
Capital International Investors	$290.7M	751.8K	-299.1K	Trimmed	0.06%	Filing ↗
UBS Group AG	$286.1M	739.8K	+4.7K	Added	0.04%	Filing ↗
ACR Alpine Capital Research, LLC	$285.4M	737.9K	+737.9K	New	4.05%	Filing ↗
Millennium Management LLC	$281.4M	727.6K	-191.6K	Trimmed	0.20%	Filing ↗
Royal Bank of Canada	$268.8M	694.9K	+199.6K	Added	0.05%	Filing ↗

1–50 of 60

Executive pay and performance

What the chief executive and the other named officers were paid, as reported and as actually paid, next to the shareholder return and net income, from each proxy's pay-versus-performance table.

Pay versus performance

6 fiscal years · from each proxy (DEF 14A)

Fiscal year	CEO pay, as reported	CEO pay, actually paid	Other officers, as reported (average)	Other officers, actually paid (average)	Shareholder return, $100	Peer return, $100	Net income	Adjusted Shareholders' Net Income	Proxy
FY ending 31 Dec 2025	$22.6M	$18.8M	$7.2M	$5.9M	$117	$148	$5.66Bⁿ	$6.74B	DEF 14A 27 Mar 2026
FY ending 31 Dec 2024	$20.5M	$-4.0M	$6.3M	$-0.3M	$121	$129	$5.97Bⁿ	$7.68B	DEF 14A 27 Mar 2026
FY ending 31 Dec 2023	$21.9M	$16.2M	$8.9M	$8.2M	$152	$126	$5.99Bⁿ	$7.84B	DEF 14A 27 Mar 2026
FY ending 31 Dec 2022	$20.9M	$35.3M	$6.7M	$10.9M	$163	$124	$5.89Bⁿ	$7.01B	DEF 14A 27 Mar 2026
FY ending 31 Dec 2021	$19.3M	$50.4M	$6.4M	$15.7M	$146	$126	$6.15Bⁿ	$6.30B	DEF 14A 27 Mar 2026
FY ending 31 Dec 2020	$17.1M	$28.3M	$5.4M	$7.3M	$108	$113	$4.57B	$5.98B	DEF 14A 28 Mar 2025

Each year from the newest proxy that reports it. Pay actually paid follows the SEC's definition and can be below zero when share awards fall in value. ⁿ the proxy's net income differs from the 10-K or was tagged without its scale: hover for which.

Shareholder votes

The vote count on every proposal at each meeting, from the company's 8-K.

Meeting

8-K, item 5.07, filed 13 May 2026

Proposal	For	Against or withheld	Abstain	Broker non-votes	For, % of for and against	Result
Proposal 1 (the filing doesn't name it)
Gail K. Boudreaux	177,978,713	1,714,229	110,827	14,637,570	99.0%	–
Robert L. Dixon, Jr.	174,098,489	5,590,793	114,487	14,637,570	96.9%	–
Deanna D. Strable	175,331,822	4,360,980	110,967	14,637,570	97.6%	–
Proposal 2 (the filing doesn't name it)
All shares voting	172,363,616	7,240,619	199,534	14,637,570	96.0%	–
Proposal 3 (the filing doesn't name it)
All shares voting	175,183,332	19,141,697	116,310	–	90.1%	–
Proposal 4 (the filing doesn't name it)
All shares voting	15,587,160	162,924,290	1,292,319	14,637,570	8.7%	–

Counts as the company reports them in its 8-K. A result shows when the filing states one. Meetings since 2023.

Dividends and buybacks

Dividend per share, the cash paid and the shares bought back, each fiscal year.

Dividend per share, each fiscal year

$0$2$4$6

'10'13'16'19'22'25


FY2025	–	$1.5B	$2.6B
FY2024	–	$1.5B	$2.9B
FY2023	$5.92	$1.4B	$2.7B
FY2022	$5.12	$1.2B	$2.3B
FY2021	$4.52	$1.1B	$1.9B
FY2020	$3.80	$954.0M	$2.7B
FY2019	$3.20	$818.0M	$1.7B
FY2018	$3.00	$776.0M	$1.7B
FY2017	$2.70	$704.9M	$2.0B
FY2016	$2.60	$684.0M	$0

1–10 of 16

Peers

Companies in the same industry, largest first, on the same measures.

Company	Market value	Revenue, 12 months	Revenue growth	Operating margin	Net margin	ROE	P/E	EV/EBITDA
Elevance Health, Inc.this company	$95.1B	$201.8B	3.6%	2.7%	2.5%	11.5%	18.8×	16.7×
UnitedHealth Group Inc.	$378.4B	$450.1B	6.5%	4.8%	3.1%	13.5%	26.9×	16.3×
Cigna Group	$81.1B	$282.4B	7.8%	3.5%	2.3%	15.1%	12.7×	8.4×
Humana Inc.	$50.7B	$145.7B	18.3%	1.9%	0.9%	6.7%	40.0×	17.3×
Centene Corp.	$34.7B	$202.9B	13.9%	-2.8%	-2.5%	-22.6%	–	–
Molina Healthcare, Inc.	$10.9B	$44.1B	-0.9%	0.4%	-0.1%	-1.2%	–	30.5×
Alignment Healthcare, Inc.	$1.7B	$4.6B	37.2%	1.2%	0.9%	15.4%	42.5×	15.1×
Trupanion, Inc.	$1.3B	$1.5B	11.8%	1.6%	1.5%	5.7%	55.3×	31.4×

What the company does

Elevance Health sells health cover and health services. It served approximately 45.2 million medical members through its affiliated health plans at the end of 2025, and describes itself as one of the largest health insurers in the United States by medical membership. Its position rests on something structural: it is an independent licensee of the Blue Cross and Blue Shield Association, which gives it the Blue brands in a defined list of states.

Where it holds the Blue licence

It is the Blue Cross licensee for California, and the Blue Cross and Blue Shield licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri excluding 30 counties around Kansas City, Nevada, New Hampshire, New York in the New York City metropolitan area and upstate, Ohio, Virginia excluding the Northern Virginia suburbs of Washington D.C., and Wisconsin. In most of those areas it trades as Anthem Blue Cross, or Anthem Blue Cross and Blue Shield. It also works through arrangements with other Blue licensees and other partners, and serves members in many states under the Wellpoint, Carelon, MMM and Simply Healthcare names.

From the 10-K for the year to 31 Dec 2025, filed 6 Feb 2026 · the filing ↗

Elevance Health, Inc.NYSE · S&P 500